Bayer counted the cost of its expensive Roundup weedkiller settlement in the second quarter with a €9.5 billion net loss made worse by lower sales in its pharma and consumer he
Roche’s tumour-agnostic therapy Rozlytrek has been approved in the European Union for people with tumours with the NTRK mutation, meaning Bayer’s class rival faces competition in Europe for
The FDA has granted a faster Priority Review for Bayer and Merck & Co’s filing for vericiguat, which is being developed for chronic heart failure with reduced ejection fraction, followi
The de-prioritisation of face-to-face interactions between patients and healthcare professionals in the wake of COVID-19's current emergency has motivated a lot of changes in healthcare sys
German pharma and chemicals group Bayer may finally have put long-running litigation over its weedkiller Roundup in its rear view mirror – but at an eye-watering cost of more t
The UK’s National Institute for Health and Care Excellence (NICE) has cleared Roche’s Rozlytrek for NTRK fusion-positive solid tumours, shortly after clearing a rival drug from